

Information Governance

3 May 2017

**Our Ref:** RFI 20210

Dear

**Freedom of Information Act 2000  
Information in Relation to Number of Patients with HER2 Breast Cancer  
Currently being Treated with Specific Drugs**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for the information relating to the above which you requested on 20 April 2017.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

Under the terms of the legislation, if you are unhappy with this response you have the right to seek a review within the Trust in the first instance. If you wish to do so, please write to me at the address below.

If after such a review you are still unhappy with the response, you have the right to appeal to the Information Commissioner who will undertake an independent review. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, SK9 5AF.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**L McAree (Miss)  
Head of Information Governance &  
Directorate Support**

Enc

Q1. *In your trust, how many patients with HER2 breast cancer are currently being treated (in the past 3 months available) with the following products;*

*Herceptin IV (trastuzumab IV) only*

*Herceptin SC (trastuzumab SC) only*

*Perjeta (pertuzumab) combined with Herceptin/Docatexel*

*Kadcyla (trastuzumab emtansine)*

*Tyverb (lapatinib)*

A1. Please see response provide below in Table 1:-

**Table 1**

<b>Drug</b>	<b>Number of Patients Treated</b>
Herceptin IV (trastuzumab IV) only	<5 patients
Herceptin SC (trastuzumab SC) only	22 patients
Perjeta (pertuzumab) combined with Herceptin/Docatexel	<5 patient
Kadcyla (trastuzumab emtansine)	None
Tyverb (lapatinib)	None